Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more
Start a new interaction query Switch to Table View

Generate a personalised report in PDF format

Potential Interaction

Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF)

Ecstasy (MDMA)

Quality of Evidence: Very Low

Summary:

Coadministration has not been studied. MDMA is metabolized mainly by CYP2D6. Elvitegravir/cobicistat could potentially increase MDMA concentrations although to a moderate extent as cobicistat is a weak inhibitor of CYP2D6. Ensure the patient is aware of signs/symptoms of MDMA toxicity. Emtricitabine and tenofovir alafenamide do not interact with this metabolic pathway.

Description:

(See Summary)

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2024 The University of Liverpool. All rights reserved.